December 14, 2022Open Access
View Full PaperChlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events
Structured PICO
Does chlorthalidone reduce major cardiovascular outcome events or non-cancer-related deaths compared to hydrochlorothiazide in patients with hypertension?
P
Population
Patients with hypertension
I
Intervention
Chlorthalidone at doses commonly used in clinical practice
C
Comparator
Hydrochlorothiazide at doses commonly used in clinical practice
O
Outcome
Major cardiovascular outcome events or non-cancer-related deathshard clinical
In a large pragmatic trial, chlorthalidone did not demonstrate superiority over hydrochlorothiazide for reducing major cardiovascular events or non-cancer-related deaths in patients with hypertension.
Abstract
In this large pragmatic trial of thiazide diuretics at doses commonly used in clinical practice, patients who received chlorthalidone did not have a lower occurrence of major cardiovascular outcome events or non-cancer-related deaths than patients who received hydrochlorothiazide. (Funded by the Veterans Affairs Cooperative Studies Program; ClinicalTrials.gov number, NCT02185417.).